<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330654</url>
  </required_header>
  <id_info>
    <org_study_id>2010030</org_study_id>
    <nct_id>NCT01330654</nct_id>
  </id_info>
  <brief_title>Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers</brief_title>
  <official_title>Using Heart Rate Variability to Analyze the Effect of Beta Blockers on Intermediate Risk Patients Undergoing Laparoscopic Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta blockers have been shown to decrease the risk of intraoperative cardiac events in
      patients at high cardiac risk. However, they have also been associated with side effects (for
      instance, stroke.) The role of beta blockers in patients at intermediate cardiac risk
      undergoing surgery is controversial. Heart rate variability is a way of evaluating the
      cardiac function of a patient. Decreased heart rate variability is associated with early
      cardiac death in patients with congestive heart failure (CHF) and after a heart attack. It
      has been shown to transiently decrease in patients in hemorrhagic shock after trauma and
      returns to normal after resuscitation in trauma and burn patients. The investigators
      hypothesize that beta blockers will maintain pre operative heart rate variability in patients
      with intermediate risk of cardiac events during operative intervention with laparoscopic
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no patients were enrolled. Study was closed prior to study start.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiac Event Risk</condition>
  <arm_group>
    <arm_group_label>Beta blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will receive no additional treatment prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol</intervention_name>
    <description>50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.</description>
    <arm_group_label>Beta blocker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 40-75 years old

          -  intermediate risk of adverse cardiac events:

               -  renal insufficiency (CrCl &lt; 60)

               -  diabetes mellitus

               -  two of the following:

                    -  age &gt; 50

                    -  obesity

                    -  hypertension

                    -  hyperlipidemia

                    -  hypercholesterolemia

                    -  prior stroke

               -  undergoing an elective laparoscopic abdominal surgery less than three hours:

                    -  cholecystectomy

                    -  ventral hernia repair

                    -  umbilical hernia repair

                    -  gastric bypass or gastric banding

        Exclusion Criteria:

          -  currently taking a beta blocker

          -  prior heart attack

          -  rhythm other than sinus on ECG

          -  contraindication to beta blockers:

               -  decompensated CHF

               -  severe valvular disease

               -  asthma

               -  COPD

               -  hypersensitivity to beta blockers

               -  heart rate &lt; 60

          -  currently taking a calcium channel blocker

          -  urgent or emergent surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Wessel, MD</last_name>
    <role>Study Director</role>
    <affiliation>UCSF Fresno Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Regional Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.physionet.org</url>
    <description>PhysioNet is a database of physiologic signals and contains information on heart rate variability</description>
  </link>
  <reference>
    <citation>Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. Circulation. 2006 Jun 6;113(22):2662-74.</citation>
    <PMID>16754815</PMID>
  </reference>
  <reference>
    <citation>Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996 Mar;17(3):354-81.</citation>
    <PMID>8737210</PMID>
  </reference>
  <reference>
    <citation>Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987 Feb 1;59(4):256-62.</citation>
    <PMID>3812275</PMID>
  </reference>
  <reference>
    <citation>Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999 Dec 9;341(24):1789-94.</citation>
    <PMID>10588963</PMID>
  </reference>
  <reference>
    <citation>Beckers F, Verheyden B, Ramaekers D, Swynghedauw B, Aubert AE. Effects of autonomic blockade on non-linear cardiovascular variability indices in rats. Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):431-9.</citation>
    <PMID>16700875</PMID>
  </reference>
  <reference>
    <citation>Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006 Nov;152(5):983-90.</citation>
    <PMID>17070177</PMID>
  </reference>
  <reference>
    <citation>POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, MÃ¡laga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12.</citation>
    <PMID>18479744</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jim Davis, Interim Program Director, Department of Surgery</name_title>
    <organization>UCSF Fresno</organization>
  </responsible_party>
  <keyword>Intermediate risk of adverse cardiac event</keyword>
  <keyword>Undergoing laparoscopic surgical procedure</keyword>
  <keyword>Age forty to seventy five</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

